The Consent Ladder in Pharma: Turning Permission into Omnichannel Performance

Download↗Talk to us

Authors

Devashish Satarkar profile photo

Devashish Satarkar

AVP, Global Head - Omnichannel Marketing & Media Operations

Jaclene D’Ambra profile photo

Jaclene D’Ambra

SVP, BioPharm Communications, an Indegene Company

Nilesh Gokhale profile photo

Nilesh Gokhale

Director, Omnichannel Campaign Operations

Executive Summary

Across the EU, HCPs now delete more pharma outreach than they read. The brands they engage with and the ones they ignore are not separated by content quality — they are separated by consent quality. Permission, not promotion, is the new performance driver. Yet, building a scalable and compliant HCP consent base remains one of the most persistent challenges in pharma marketing. Traditional models relying heavily on field representatives are resource-intensive and difficult to scale. Omnichannel initiatives are growing, but many pharma organizations continue to face challenges with fragmented data, disconnected capabilities, and inconsistent customer experiences that limit scalable engagement and longterm performance

Drawing on Indegene and BioPharm Communications’ omnichannel operating model, backed by strategic consulting expertise, and 20+ years of earned and acquired precision HCP engagement data, this paper presents a strategic framework that integrates valueled content, omnichannel activation, geography-aware governance, progressive profiling, and comprehensive preference management, positioning consent as the foundation of a connected, customer-centric omnichannel experience

Key Challenges in Building a Compliant HCP Consent Base

HCPs are time-constrained and selective about who they engage with. Generic or poorly timed consent requests are easily ignored. Without a compelling value proposition, many HCPs decline to opt in, especially when digital fatigue or message overload sets in.

Geography-Specific Regulatory Consideration

Consent strategies must be tailored to regional regulatory nuances to ensure scalability and defensibility.

Geography-Specific Regulatory Consideration
  • European Union: GDPR and ePrivacy require explicit, purpose-specific, granular consent with audit trails and easy withdrawal.

  • United Kingdom: UK GDPR aligns with EU standards but includes localized enforcement practices.

  • United States: HIPAA governs protected health information; state laws (CCPA/CPRA) introduce consumer-level protections

  • India: The Digital Personal Data Protection (DPDP) Act mandates clear notice, consent capture, and withdrawal transparency.

  • APAC & Middle East: Emerging frameworks require localization, cross-border transfer safeguards, and language-specific consent design.

The Two-Pillar Approach to Consent Building: Value-Led Content and Omnichannel Activation

Overcoming the barriers to digital HCP consent collection requires more than tactical fixes or one-off campaigns. It demands a strategic, experience-driven approach that places the HCP at the center of every interaction.

Consent cannot simply be requested or assumed; it must be earned. The path to earning consent is through delivering relevant, timely, and trusted experiences that create meaningful value for HCPs. Many consent strategies fall short because they treat consent as a legal checkbox or a backend process rather than as an opportunity to build trust, credibility, and long-term relationships through meaningful engagement.

By focusing on two core pillars, pharma brands can transform consent collection from a compliance exercise into a strategic engagement mechanism that fosters trust, loyalty, and long-term HCP relationships. They are:

  • 1. Value-Led Content – making the opt-in feel worthwhile for HCPs

  • 2. Strategic Omnichannel Activation – delivering that value in the right context

Diagram showing a two-pillar approach to transforming HCP consent collection into a strategic engagement mechanism.

These pillars are interdependent. Even the most compelling content will fail if it does not reach HCPs through the appropriate channels and at the right time. Conversely, a sophisticated omnichannel strategy will not succeed if the content itself does not provide clear value.

And while these two pillars are essential, they also depend on a third and often underdeveloped capability: progressive profiling and identity resolution (covered further along in the report), which ensures that each interaction contributes to a unified and continuously enriched HCP profile that evolves alongside changing engagement behaviors, patient dynamics, and practice settings.

Pillar 1: Value-Led Content

At the core of every successful consent ladder is a simple truth: HCPs do not provide consent for their own sake. They opt in when the value is clear and immediate. This is why a content-led, objective-driven approach should be the first building block of any modern consent collection strategy.

Forward-thinking pharma organizations are reframing consent as a mutual exchange, where valuable content serves as the gateway to opt-in.

Examples of Value-Led Content

Illustration Showing Examples of Value-Led Consent

High-quality, relevant content motivates HCPs to engage while also building trust and long-term relationships.

Scientific Thought Leadership

Providing access to credible, unbiased scientific resources such as clinical updates, whitepapers, peer-reviewed studies, and treatment guidelines encourages HCPs to opt in for ongoing updates while helping establish credibility and trust through less promotional, more educational engagement. Hosting this content on HCP portals positions consent as the gateway to staying informed and professionally up to date.

1 / 7

Pillar 2: Omnichannel Activation

Even the most valuable content will have limited impact if it is not delivered through the right channels. A strategic omnichannel operating model is essential to reach HCPs where they are and maximize opportunities, or moments, to capture consent in a compliant, efficient, and contextually relevant way. Below is an overview of key channels for successful HCP consent activation.

1

Endemic HCP Platforms

Endemic HCP platforms (e.g., precision HCP engagement ecosystems operated by BioPharm Communications) provide a trusted, compliant environment to reach verified medical professionals. They support content syndication, gated engagement, and interest-based targeting in line with GDPR and local regulations. First-party endemic ecosystems anchored in earned behavioral data, developed through years of consented HCP interactions, consistently deliver higher opt-in quality and durability than open-exchange or list-broker alternatives. These platforms can be leveraged to:

  • Engage HCPs with scientific articles, case discussions, and CME opportunities

  • Run gated campaigns to promote webinars or whitepapers, with embedded opt-in forms

  • Build specialty-targeted opt-in journeys with high trust and compliance

Endemic platforms are particularly effective for consent acquisition in highly regulated regions and for hard-to-reach specialties, especially where rep presence is limited.

2

Third-Party Emailers and Publishers

Third-party medical publishers and email service providers offer access to pre-qualified HCP lists, particularly in regions where direct access is limited. These channels help in:

  • Reaching niche specialties or low-engagement geographies

  • Running co-branded or neutral awareness campaigns with embedded opt-in forms

  • Driving traffic to consent-gated landing pages or HCP portals

Third-party campaigns are effective for top-of-funnel awareness and initial consent capture but must be orchestrated alongside first-party CRM programs to create a more connected and consistent customer experience across channels. Most campaigns are non-branded and focus on scientific or thought-leadership content, minimizing compliance risk. It is critical to audit third-party HCP lists and ensure appropriate opt-in permissions and documentation in line with GDPR and local regulations.

3

Social Media

LinkedIn, Doximity, Sermo, etc. are underutilized channels for HCP outreach. Professional social platforms allow non-personalized engagement, especially in B2B healthcare settings. This channel can be used to:

  • Promote thought leadership content or event invitations with lead-gen forms

  • Run interest-based campaigns for specialty targeting

  • Collect soft opt-ins through value-based gated content

  • Sponsored InMail and lead-gen ads introduce value and guide HCPs into opt-in journeys without breaching privacy norms.

4

Paid Media, Including Search Engine Marketing (SEM) and Programmatic Display Advertising

Intent-based Paid Media in Omnichannel PharmaPaid Media Channels such as Google Search and programmatic display offer scalable, compliant reach to HCPs. These campaigns work best with non-personalized disease awareness or therapy area content. Within this mix, identity-verified HCP programmatic consistently outperforms open-exchange programmatic. Leading precision HCP partners report match rates approaching 85% on display and up to 100% on direct-mail-equivalent targeting, meaningfully above industry norms for aggregated audiences and a key differentiator for brands seeking both reach and data quality.

  • Paid search and display can be used to:

  • Drive traffic to gated landing pages, HCP support tools, congress content, or whitepapers

  • Execute geo-targeted campaigns aligned with local compliance rules

  • Initiate opt-in journeys based on user search behavior

Success in these channels depends heavily on precision planning, including keyword strategy, geographic filters, and persona-based audience segmentation.

5

HCP Portals (Owned)

HCP portals serve as always-on, consent-friendly ecosystems designed to deliver continuous value and maintain long-term engagement. While often used as a downstream destination for other channels, portals can also drive organic, inbound engagement when optimized. Key capabilities include:

  • Ongoing value delivery through gated access

  • Real-time preference and consent updates

  • Integration with MDM/CRM systems for compliance and personalization

To maximize impact, combine non-branded, SEO-optimized pre-login content with gated branded assets. Portals are ideal for long-term consent retention, not just acquisition.

6

Webinars and Congress Platforms

Webinars and congresses are high-intent environments where HCPs are already engaged and receptive. These channels offer natural, compliant opportunities to initiate or reinforce consent. Consent can be collected during:

  • Pre-registration

  • Live Q&A or session interactions

  • Access to post-event content, including recordings and highlights

These environments are particularly effective because HCPs are actively seeking information, making them more likely to engage in the consent process.

7

Field Teams and Representative Engagement

Field teams remain an important component of a modern omnichannel activation strategy. While their reach may be more limited than in traditional engagement models, they continue to play a valuable role in delivering personalized interactions, reinforcing scientific exchange, and building trusted HCP relationships. Integrating field engagement bidirectionally with digital channels helps create value-based message continuity across the customer journey while enabling more coordinated and contextually relevant omnichannel experiences.

A single channel is rarely sufficient. Multi-touch journeys that align content, channel, timing, and context yield the best results. The most effective journeys are behavioral in nature, adapting the next interaction or communication based on engagement signals and real-world behaviors to deliver more relevant experiences at key moments in time.

Use a broad-reach omnichannel mix, such as paid search or third-party emailers, to raise awareness and capture initial opt-ins through value-based content. Nurture these leads through owned platforms like email, portals, and webinars to deepen engagement. Consent performance should be tracked across all touchpoints, with clear attribution models to better understand engagement quality, profile enrichment, and long-term customer value.

Organic vs Procured Consent: Quality Matters

Not all consent is created equal. The source and context in which consent is obtained directly influences its quality, durability, and long-term engagement potential.

Organic consent, earned through owned ecosystems such as HCP portals, webinars, and gated content, typically reflects higher intent and stronger trust. These interactions are rooted in direct value exchange, where HCPs actively choose to engage based on relevance and perceived benefit. As a result, organic consent tends to deliver superior engagement rates, richer data profiles, and more sustainable long-term relationships.

In contrast, procured consent, acquired through third-party publishers, databases, or partner ecosystems, provides immediate scale and access to broader audiences. However, if these audiences are not nurtured properly, procured consent can lack contextual depth and brand affinity, which can impact downstream engagement quality and retention.

A mature consent strategy does not treat these approaches as mutually exclusive. Instead, it leverages procured consent to accelerate reach and awareness while systematically investing in organic ecosystems to build high-trust, first-party relationships. Over time, the objective should be to transition from dependence on external data sources toward a robust, self-sustaining consent infrastructure anchored in owned channels. The strongest organic foundations are built on earned behavioral data, first-party HCP relationships developed over years of consented engagement, not inferred or purchased profiles. This distinction is what makes progressive profiling and omnichannel orchestration possible at scale, and it is where precision HCP engagement partners have the clearest structural advantage over list-driven or aggregator-driven alternatives.

Progressive Profiling as a Strategic Lever

Progressive profiling enables brands to collect HCP data gradually across multiple touchpoints rather than through long, intrusive forms. Each interaction deepens profile intelligence, such as specialty, interests, frequency, and channel preferences, Four Omnichannel Trends Reshaping Pharma Communicationsenhancing personalization while maintaining trust. Progressive profiling, however, only works when anchored to a persistent HCP identity graph. Without identity resolution, every new touchpoint creates a fresh record instead of enriching an existing one, and profiles fragment rather than compound. This is why progressive profiling is an operational capability as much as a marketing tactic, and why it sits at the center of top-performing precision HCP partners’ approach to HCP engagement. Progressive profiling helps:

  • Boost initial conversion rates

  • Improve long-term data accuracy

  • Reduce form-fatigue

  • Increase omnichannel orchestration capabilities

Opt-Out and Preference Management

In consent management for omnichannel engagement, while gathering opt-ins is essential, it is equally important to offer clear and accessible opt-out options for HCPs, fostering a more transparent and trustworthy ecosystem. A compliant consent ecosystem must include seamless and granular opt-out mechanisms. Withdrawal should be simple, channel-specific, and automatically synchronized across CRM and marketing systems.

Channel-level unsubscribe controls

Channel-level unsubscribe controls allow HCPs to opt out of specific communication channels while remaining subscribed to others. Instead of a binary “unsubscribe from everything” option, HCPs can choose their preferred communication modes. Providing this level of control improves both compliance and user experience.

Preference center self-service management

A preference center is a centralized portal where HCPs can view, modify, and manage their communication preferences. Rather than forcing users to unsubscribe entirely, preference centers empower them to tailor engagement according to their needs. Typical options available in a preference center include:

  • Therapeutic areas of interest

  • Communication channels (email, webinar, portal notifications)

  • Content types (clinical research, congress updates, patient support tools)

  • Frequency of communication

This level of customization ensures communication remains relevant and welcomed.

Automated suppression logic across systems

Opt-out signals must propagate immediately across all marketing and operational systems. Without automated suppression logic, an HCP who unsubscribes from email may still receive communications from:

  • CRM-driven campaigns

  • Webinar tools

  • Marketing automation platforms

  • Third-party outreach systems

Automated suppression ensures no further communications are sent once consent is withdrawn. Organizations should also maintain clearly documented privacy policies and automated governance processes to support adherence to geography-specific regulations, including GDPR, CCPA, and other evolving privacy frameworks. These processes should ensure that consent updates and opt-out requests are consistently synchronized across systems and channels in accordance with local compliance requirements.

Audit logging of withdrawal timestamps

Regulatory frameworks such as GDPR require organizations to maintain clear audit trails for both consent capture and withdrawal. Every opt-out action should record:

  • Timestamp of withdrawal

  • Channel affected

  • Source of request (email link, portal, customer support, etc.)

  • System recording the change

This information is stored within the Pharma Consent Management Best Practicesconsent management system or CRM. Audit logging ensures traceability and defensibility.

Periodic re-consent workflows

Consent validity may change over time due to:

  • Regulatory updates

  • System migrations

  • Data governance policies

  • Inactive user profiles

Periodic re-consent workflows help maintain a fresh, compliant, and engaged HCP database.

The Digital Consent Ladder: From Unknown to Advocate

Building a robust HCP consent base is not a one-time activity; it is a progressively laddered omnichannel journey that moves individuals from unengaged and anonymous to fully opted-in and personally engaged. A well-orchestrated consent journey ensures compliance, enhances trust, and unlocks long-term value for both the HCP and the organization.

Flowchart Showing Six Key Steps on the Digital Consent Ladder

Six Key Steps on the Digital Consent Ladder

Step 1: Attract (Awareness)

Use digital channels such as LinkedIn, paid search, endemic platforms, and third-party emailers to promote value-driven content. Focus on building awareness and interest with soft opt-in nudges, such as gated tools, webinar invitations, or downloadable assets, without immediately requesting personal data.

1 / 6

Strategic Business Impact

  • Scalable HCP coverage across geographies.

  • Deeper HCP profiles

  • Lower cost per opt-in while complementing and extending field engagement models

  • Increased ROI on scientific content.

  • Always-on consent infrastructure.

  • Enhanced personalization and omnichannel performance.

Case Study: Scaling HCP Engagement Through Consent Maturity

Context

A mid-sized pharma company in the EU (cardiology portfolio) aimed to reduce dependence on field reps, build a compliant and scalable HCP engagement model, and improve ROI from digital campaigns.

Key Challenges

The organization faced a set of interconnected challenges that limited both scale and effectiveness of HCP engagement:

01.

Over-Reliance on Procured Data

Engagement efforts were heavily dependent on third-party HCP lists, resulting in limited control over data quality, inconsistent consent validity, and low long-term engagement.

02.

Limited First-Party (Organic) Consent

The absence of strong owned ecosystems meant that organic consent acquisition was minimal, restricting the ability to build high-trust, direct relationships with HCPs.

03.

Channel Concentration

Email was the primary, and often only, channel used for engagement. This limited reach, reduced engagement diversity, and constrained the ability to orchestrate meaningful omnichannel journeys.

04.

Absence of a Structured Consent Lifecycle

Consent collection was treated as a one-time activity rather than a continuous journey. There were no mechanisms for validation, enrichment, preference management, or re-consent, resulting in stagnant and underutilized HCP profiles.

The Solution: Consent-Led Digital Transformation

To address these challenges, a structured, multi-dimensional omnichannel transformation exercise was implemented, anchored in the principles of value exchange, omnichannel activation, and lifecycle-based consent management.

A robust content ecosystem was developed to create meaningful entry points for consent acquisition and sustained engagement. Key initiatives included:

  • Gated access to clinical guidelines to drive high-intent opt-ins

  • KOL-led webinars to deliver expert-driven scientific engagement

  • Interactive treatment calculators addressing real-world clinical needs

  • Congress highlights and summaries to extend event value beyond attendance

This approach repositioned consent as a gateway to relevant, high-value scientific content, significantly improving opt-in quality and intent.

Consent Journey Funnel (6-Month Performance)

StageMetricVolumeConversion Rate
AwarenessHCPs reached120,000-
EngagementClicks/Visits24,00020%
Initial ConsentEmail opt-ins8,40035%
Validated ConsentDouble opt-in confirmed6,30075%
Omnichannel ConsentWebinar + email3,15050%
Enriched ProfilesPreference completed1,90060%
High-Value EngagementProgram/tool usage95050%

Key Insights

  • Drop-off is highest between awareness and initial consent but improves significantly with strong value proposition and simplified journeys.

  • Organic consent significantly outperforms procured consent in engagement metrics.

  • Progressive profiling improves personalization and increases click-through rates while reducing unsubscribe rates.

  • Omnichannel consent leads to higher engagement, retention, and participation rates.

  • Digital-first consent strategy reduces cost per engagement and improves scalability.

Key Outcomes and Business Impact

  • 2.5x increase in qualified HCP base

  • ~40% reduction in cost per consent

  • Shift toward first-party data ecosystem

  • Improved compliance and audit readiness

The case demonstrates that consent maturity directly drives engagement quality and commercial performance. Organizations that progressively build, enrich, and activate consent create sustainable, scalable growth in a privacy-first ecosystem.

Conclusion: Consent as Infrastructure

In a privacy-first era, permission is the new performance driver. Pharma organizations that design geography-aware, value-led, progressively enriched consent-driven omnichannel ecosystems, supported by strong opt-out governance, will outperform those treating consent as a one-time campaign activity rather than as part of a customer-centric engagement experience built on trust and long-term value. Consent maturity and a mature omnichannel omnichannel operating model are inseparable.

The future of HCP omnichannel engagement belongs to those who treat consent not as a hurdle but as an opportunity to deliver value strategically, respectfully, and consistently. In doing so, consent becomes a meaningful foundation for digital growth and long-term trust. Connect With IndegeneTalk to us to learn more.

Download↗Talk to us

Authors

Devashish Satarkar profile photo

Devashish Satarkar

AVP, Global Head - Omnichannel Marketing & Media Operations

Jaclene D’Ambra profile photo

Jaclene D’Ambra

SVP, BioPharm Communications, an Indegene Company

Nilesh Gokhale profile photo

Nilesh Gokhale

Director, Omnichannel Campaign Operations